Archive for the ‘TNK Therapeutics’ Category

TNK Therapeutics, Inc.

September 4th, 2015 | Posted in 2015, Sorrento Therapeutics, TNK Therapeutics

TNK Therapeutics, Inc, a wholly owned subsidiary of Sorrento Therapeutics, has acquired the multiple preclinical and clinical stage chimeric antigen receptor immunotherapy programs, as well as underlying CAR-T technology, via the purchase of two privately-held biotech companies.